TScan Therapeutics Inc. (TCRX), which continues to make meaningful progress across its pipeline, remains on track to provide a clinical update at the end of this year.
This clinical-stage biopharmaceutical company is developing T cell receptor-engineered T cell therapies (TCR-T) for the treatment of cancer. Patients' own T cells are genetically engineered to recognize and eliminate their cancer. Using one of its proprietary platform technologies, TargetScan, the company analyses the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system naturally recognizes and eliminates tumor cells in these patients.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.